{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:33:46Z","timestamp":1787981626219,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.ejphar.2011.05.021","type":"journal-article","created":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T22:03:13Z","timestamp":1306274593000},"page":"196-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Protective effects of cortex fraxini coumarines against oxonate-induced hyperuricemia and renal dysfunction in mice"],"prefix":"10.1016","volume":"666","author":[{"given":"Jian-Mei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Chang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Dong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2011.05.021_bb0005","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.1074\/jbc.C800156200","article-title":"Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans","volume":"283","author":"Anzai","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0010","doi-asserted-by":"crossref","first-page":"F612","DOI":"10.1152\/ajprenal.00139.2009","article-title":"Mouse GLUT9: evidences for a urate uniporter","volume":"297","author":"Bibert","year":"2009","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0015","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.taap.2008.09.018","article-title":"Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling","volume":"233","author":"Brown","year":"2008","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/clinchem\/17.3.158","article-title":"A simplified alkaline phosphotungstate assay for uric acid in serum","volume":"17","author":"Carroll","year":"1971","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","article-title":"Relationship of uric acid with progression of kidney disease","volume":"50","author":"Chonchol","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0030","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11095-005-2486-x","article-title":"Differential contributions of rOat1 (Slc22a6) and rOat3 (Slc22a8) to the in vivo renal uptake of uremic toxins in rats","volume":"22","author":"Deguchi","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0035","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(08)61343-4","article-title":"Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide study","volume":"372","author":"Dehghan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2011.05.021_bb0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2337\/dc07-1276","article-title":"High serum uric acid as a novel risk factor for type 2 diabetes","volume":"31","author":"Dehghan","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2011.05.021_bb0045","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10157-005-0368-5","article-title":"Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease","volume":"9","author":"Enomoto","year":"2005","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2011.05.021_bb0055","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0006-2952(03)00466-0","article-title":"Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1, rOAT3 and rOCT2","volume":"66","author":"Habu","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0060","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.bcp.2004.12.004","article-title":"Restored expression and activity of organic ion transporters rOAT1, rOAT3 and rOCT2 after hyperuricemia in the rat kidney","volume":"69","author":"Habu","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0065","first-page":"1","article-title":"Coumarin glycoside from the stembark of Fraxinus sieboldiana var. angustata","volume":"14","author":"Hahn","year":"1983","journal-title":"Saengyak Hakhoechi"},{"key":"10.1016\/j.ejphar.2011.05.021_bb0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.ASN.0000107560.80107.19","article-title":"Function and localization of urate transporter 1 in mouse kidney","volume":"15","author":"Hosoyamada","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0075","doi-asserted-by":"crossref","first-page":"F1080","DOI":"10.1152\/ajprenal.90767.2008","article-title":"Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement","volume":"297","author":"Hu","year":"2009","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0080","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/sj.ki.5000407","article-title":"ABC transporter expression profiling after ischemic reperfusion injury in mouse kidney","volume":"69","author":"Huls","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.103.053298","article-title":"Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3)","volume":"308","author":"Jonker","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0090","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00424-003-1089-9","article-title":"The SLC22 drug transporter family","volume":"447","author":"Koepsell","year":"2004","journal-title":"Pflug. Arch. Eur. J. Phy."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-2002-20262","article-title":"Aesculin possesses potent hypouricemic action in rodents but is devoid of xanthie oxidase\/dehydrogenase inhibitory activity","volume":"68","author":"Kong","year":"2002","journal-title":"Planta Med."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0100","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/bmc.497","article-title":"Non-aqueous capillary electrophoresis for separation and simultaneous determination of fraxin, esculin and esculetin in cortex fraxini and its medicinal preparations","volume":"19","author":"Li","year":"2005","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0105","first-page":"475","article-title":"Explorative clinical trial on effect of relieving pain in treatment of patients with primary acute gouty arthritis by cortex fraxini total coumarin","volume":"10","author":"Luo","year":"2005","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0110","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ajhg.2008.11.001","article-title":"Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia","volume":"83","author":"Matsuo","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jbspin.2010.02.027","article-title":"The genetic basis of hyperuricaemia and gout","volume":"78","author":"Merriman","year":"2011","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/5030","article-title":"Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter","volume":"21","author":"Nezu","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0125","first-page":"743","article-title":"Uricosuric agent","volume":"66","author":"Ohno","year":"2008","journal-title":"Nippon Rinsho."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0130","doi-asserted-by":"crossref","first-page":"11501","DOI":"10.1073\/pnas.0904411106","article-title":"Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy","volume":"106","author":"Preitner","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pharmthera.2009.09.008","article-title":"Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: pharmacological and toxicological implications","volume":"125","author":"Saito","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0140","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1349-7006.2006.00304.x","article-title":"Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats","volume":"97","author":"Shibayama","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ng.106","article-title":"SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout","volume":"40","author":"Vitart","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0150","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jep.2009.12.035","article-title":"The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice","volume":"128","author":"Wang","year":"2010","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0155","first-page":"18","article-title":"A clinical study of the glycosides from Fraxinus","volume":"43","author":"Watanabe","year":"1974","journal-title":"Folia. Pharmacol. Japon."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0160","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.1073\/pnas.0901249106","article-title":"Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout","volume":"106","author":"Woodward","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0165","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1254\/fpj.64.714","article-title":"Pharmacologic studies on the components of Fraxinus japonica","volume":"64","author":"Yamagami","year":"1968","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"10.1016\/j.ejphar.2011.05.021_bb0170","first-page":"3","article-title":"Clinical trial of cortex fraxini total coumarin in treating primary hyperuricaemia","volume":"24","author":"Yu","year":"2008","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.05.021_bb0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpba.2007.12.009","article-title":"Simultaneous analysis of coumarins and secoiridoids in Cortex Fraxini by high-performance liquid chromatography-diode array detection\u2013electrospray ionization tandem mass spectrometry","volume":"47","author":"Zhou","year":"2008","journal-title":"J. Pharm. Biomed. Anal."}],"updated-by":[{"DOI":"10.1016\/j.ejphar.2022.174740","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000}}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911005516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911005516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:13:39Z","timestamp":1757974419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299911005516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":35,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0014299911005516"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.05.021","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejphar.2022.174740","asserted-by":"object"}]},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective effects of cortex fraxini coumarines against oxonate-induced hyperuricemia and renal dysfunction in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}